376 related articles for article (PubMed ID: 24053431)
21. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
22. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
23. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
25. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
29. Bilateral testicular metastasis from prostatic adenocarcinoma mimicking an intertubular pattern of seminoma and expressing Rhamm.
Menon S; Gujral S; Bakshi G; Tongaonkar HB
J Cancer Res Ther; 2010; 6(1):97-9. PubMed ID: 20479558
[TBL] [Abstract][Full Text] [Related]
30. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
31. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
32. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
33. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Amling CL; Blute ML; Bergstralh EJ; Slezak JM; Martin SK; Zincke H
Semin Urol Oncol; 1997 Nov; 15(4):222-9. PubMed ID: 9421449
[TBL] [Abstract][Full Text] [Related]
34. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
35. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H
BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103
[TBL] [Abstract][Full Text] [Related]
38. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
39. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
40. Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated With Prostate Cancer Migration and Poor Prognosis.
Minato A; Kudo Y; Noguchi H; Kohi S; Hasegawa Y; Sato N; Hirata K; Fujimoto N
Cancer Genomics Proteomics; 2023; 20(2):203-210. PubMed ID: 36870687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]